Del-desiran Therapy for Myotonic Dystrophy Type 1

Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology · Mar 4, 2026 · 16m

This paper details the results of a Phase 1-2 clinical trial investigating a new treatment for myotonic dystrophy type 1, a progressive and currently incurable neuromuscular disease. The study tested del-desiran, an innovative therapy that combines a monoclonal antibody with an oligonucleotide to target and reduce toxic genetic transcripts in muscle tissue. Researchers found that the drug successfully reached its target, leading to a significant reduction in DMPK mRNA levels and an improvement in protein splicing patterns. While most participants experienced only mild side effects, two…